Investors nervous about Pfizer's maraviroc launch.
Monogram Biosciences (MGRM) investors are getting mighty nervous. They depend on the launch of Pfizer's HIV drug, maraviroc, to sell a test used to identify patients that will respond to the new drug.
And they are starting to blame Question Authority for the slump in Monogram stock since this blog revealed allegations by a Pfizer insider about illegal premarketing.
Here is the message string from the investors.
One of them writes, "I'm looking into this Rost guy. I don't think it's a coincidence that MGRM starting tanking around the time this guy started posting on his blog (April). Of course, if the FDA would finally approve, this is all mute. "
More maraviroc stories here.